Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab combined with anlotinib for unresectable hepatocellular carcinoma
ChiCTR2000039620Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab and anlotinib in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Progression-free survival. Started Dec 2020; status: recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000039620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039620.